We are live on ! Find out more
PCML

Pavaki Capital Management LLC Portfolio holdings

AUM $287M
This Fund
S&P 500
This Quarter Est. Return
+0.76%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$235M
AUM Growth
-$19.8M
Cap. Flow
+$13.6M
Cap. Flow %
5.79%
Top 10 Hldgs %
50.47%
Holding
162
New
31
Increased
16
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
CVX icon
Chevron
CVX
+$13.2M
2
EWS icon
iShares MSCI Singapore ETF
EWS
+$1.69M
3
ESPR
Esperion Therapeutics
ESPR
+$1.3M
4
B
Barrick Mining
B
+$1.27M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$1.19M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.8M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$5.71M
3
OGN icon
Organon & Co
OGN
+$3.01M
4
ROIV icon
Roivant Sciences
ROIV
+$868K
5
ALT icon
Altimmune
ALT
+$778K

Sector Composition

Rank Sector Weight
1 Healthcare 20.32%
2 Materials 13.21%
3 Energy 8.84%
4 Technology 4.85%
5 Communication Services 4.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GGB icon
151
Gerdau
GGB
$9.7B
$91K 0.04%
25,200
– –
SRAD icon
152
Sportradar
SRAD
$3.85B
$84.3K 0.04%
5,000
– –
WPP icon
153
WPP
WPP
$5.94B
$77.8K 0.03%
5,000
– –
SMCI icon
154
PUT
Super Micro Computer
SMCI
$20.1B
$68.3K 0.03%
3,000
-3,000
-50% -$90K
BRK.B icon
155
Berkshire Hathaway Class B
BRK.B
$1.13T
$47.9K 0.02%
100
– –
AI icon
156
C3.ai
AI
$1.59B
$42.1K 0.02%
+5,000
New +$53.6K
ALT icon
157
Altimmune
ALT
$599M
– –
-215,400
Closed -$778K
NGD
158
DELISTED
New Gold Inc
NGD
– –
-50,000
Closed -$436K
NVO
159
PUT
Novo Nordisk
NVO
$209B
– –
-10,000
Closed -$509K
ROIV icon
160
Roivant Sciences
ROIV
$26.2B
– –
-40,000
Closed -$868K
SPRY icon
161
CALL
ARS Pharmaceuticals
SPRY
$612M
– –
-1,500
Closed -$17.5K
UNCY icon
162
Unicycive Therapeutics
UNCY
$139M
– –
-90,000
Closed -$519K
3 4 5 6
7

Similar funds

GCM
GoodHaven Capital Management Millburn, New Jersey $287M AUM 9.07% 1-Year Est. Return
AWM
Avaii Wealth Management Appleton, Wisconsin $287M AUM 29.75% 1-Year Est. Return
EA
Extract Advisors Calabasas, California $287M AUM
MAG
Mayfair Advisory Group Birmingham, Alabama $286M AUM 19.6% 1-Year Est. Return
PAM
PSquared Asset Management Zurich, Switzerland $287M AUM 58.62% 1-Year Est. Return
MM
Marnell Management Farmington Hills, Michigan $288M AUM
FCG
Financial Connections Group Corte Madera, California $288M AUM 15.87% 1-Year Est. Return
A
Argentarii Cincinnati, Ohio $286M AUM 32.04% 1-Year Est. Return

Pavaki Capital Management LLC's Q1 2026 Portfolio in Review

As of Q1 2026, Pavaki Capital Management LLC held 162 positions worth $235M, down 7.8% from $255M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Pavaki Capital Management LLC deployed $13.6M of net new capital in Q1 2026, opening 31 new positions and adding to 16 existing holdings. Its largest new stake was iShares MSCI Singapore ETF: 60,000 shares worth $1.69M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 30% a quarter earlier, followed by Materials and Energy.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $8.8M trimmed.

  • Pavaki Capital Management LLC's largest Q1 2026 buy was iShares MSCI Singapore ETF: 60,000 shares worth $1.69M.
  • Pavaki Capital Management LLC added most to Chevron in Q1 2026, an estimated $13.2M increase.
  • Pavaki Capital Management LLC's biggest Q1 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $8.8M.
  • Pavaki Capital Management LLC fully exited Roivant Sciences in Q1 2026, selling an estimated $868K.
  • Pavaki Capital Management LLC's ten largest holdings make up 50% of its $235M portfolio in Q1 2026.
  • Pavaki Capital Management LLC opened 31 new positions and closed 6 in Q1 2026.
  • Pavaki Capital Management LLC's portfolio value fell 7.8% quarter-over-quarter to $235M.

Based on Pavaki Capital Management LLC's 13F filing for Q1 2026, filed 7 Aug 2026.